关于 IDH 突变型胶质瘤的世卫组织诊断更新。
Updates on the WHO diagnosis of IDH-mutant glioma.
机构信息
Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.
出版信息
J Neurooncol. 2023 May;162(3):461-469. doi: 10.1007/s11060-023-04250-5. Epub 2023 Jan 30.
PURPOSE
The WHO classification of Tumors of the Central Nervous System represents the international standard classification for brain tumors. In 2021 the 5th edition (WHO CNS5) was published, and this review summarizes the changes regarding IDH-mutant gliomas and discusses unsolved issues and future perspectives.
METHODS
This review is based on the 5th edition of the WHO Blue Book of CNS tumors (WHO CNS5) and relevant related papers.
RESULTS
Major changes include taxonomy and nomenclature of IDH-mutant gliomas. Essential and desirable criteria for classification were established considering technical developments. For the first time molecular features are not only relevant for the classification of IDH-mutant gliomas but may impact grading as well.
CONCLUSION
WHO CNS5 classification moves forward towards a classification which is founded on tumor biology and serves clinical needs. The rapidly increasing knowledge on the molecular landscape of IDH-mutant gliomas is expected to further refine classification and grading in the future.
目的
世界卫生组织（WHO）中枢神经系统肿瘤分类代表了脑肿瘤的国际标准分类。2021 年发布了第 5 版（WHO CNS5），本综述总结了 IDH 突变型胶质瘤的变化，并讨论了未解决的问题和未来的展望。
方法
本综述基于中枢神经系统肿瘤 WHO 蓝皮书第 5 版（WHO CNS5）和相关相关论文。
结果
主要变化包括 IDH 突变型胶质瘤的分类学和命名法。考虑到技术发展，为分类确定了必要和理想的标准。分子特征首次不仅与 IDH 突变型胶质瘤的分类有关，而且可能影响分级。
结论
WHO CNS5 分类朝着基于肿瘤生物学和满足临床需求的分类前进。IDH 突变型胶质瘤分子图谱的知识不断增加，预计将进一步完善分类和分级。
Zotero 插件